circRIP2 accelerates bladder cancer progression via miR-1305/Tgf-β2/smad3 pathway.
Yinjie SuWeilian FengJuanyi ShiLuping ChenJian HuangTianxin LinPublished in: Molecular cancer (2020)
Taken together, our study provides the first evidence that circRIP2 expresses differentially in bladder cancer and negatively along with the cancer progression; effective circRIP2 activity accelerates bladder cancer progression via inducing EMT by activating miR-1305/Tgf-β2/smad3 pathway. The research implies that circRIP2 might be a potential biomarker and therapeutic target for bladder cancer patients.